Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature |
| |
| Authors: | Jian-Chun Lu Long-Gen Liu Lin Lin Shu-Qin Zheng Yuan Xue |
| |
| Affiliation: | Jian-Chun Lu, Long-Gen Liu, Shu-Qin Zheng, Yuan Xue, Department of Liver Diseases, the Third People’s Hospital of Changzhou, Changzhou 213000, Jiangsu Province, ChinaJian-Chun Lu, Long-Gen Liu, Lin Lin, Shu-Qin Zheng, Yuan Xue, Institute of Hepatology, the Third People’s Hospital of Changzhou, Changzhou 213000, Jiangsu Province, ChinaLin Lin, Department of Pharmacy, the Third People’s Hospital of Changzhou, Changzhou 213000, Jiangsu Province, China |
| |
| Abstract: | Tenofovir disoproxil fumarate (TDF) is a potent nucleotide analogue with high barrier to resistance, which is recommended for multi-drug resistant hepatitis B virus (HBV) infection. However, nephrotoxicity has been reported during TDF treatment, and tenofovir alafenamide (TAF), which has comparable efficacy to TDF and improves bone and renal safety, can be used as a replacement strategy. Herein, we describe a clinical case concerning a 60-year-old individual suffering liver cirrhosis and renal dysfunction, and being infected with multidrug-resistant HBV. When failing treatment with TDF, he received TAF as a rescue therapy. TAF effectively inhibited HBV replication without worsening renal function or serum phosphorus abnormality. Furthermore, hepatocellular carcinoma (HCC) occurred during TAF treatment despite controlling the viral load. The risk of HCC could not be eliminated and should be monitored during TAF treatment. |
| |
| Keywords: | Tenofovir alafenamide Disoproxil fumarate Hepatocellular carcinoma Hepatitis B virus Mutation |
|
| 点击此处可从《World Journal of Clinical Cases》浏览原始摘要信息 |
|
